Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Journal for Immunotherapy of Cancer
|
July 15, 2025
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer
Natalie J Miller, Christina Baik, Joel W Neal, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
September 5, 2014
T-cell immunotherapy: looking forward
Jacqueline Corrigan-Curay, Hans-Peter Kiem, David Baltimore, et al.
Journal for Immunotherapy of Cancer
|
July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
Sushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Cancer Discovery
|
October 31, 2015
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo, David M Barrett, Kathryn L Black, et al.
Blood
|
July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
Hrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2021
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Claudia Rossig, Crystal Mackall, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas
Michelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Cancer Cell
|
June 13, 2025
CSF1R<sup>+</sup> myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
David Stahl, Philipp Gödel, Hyatt Balke-Want, et al.
Nature
|
November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomas
Michelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature
|
November 29, 2024
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomas
Michelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Journal for Immunotherapy of Cancer
|
July 15, 2025
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer
Natalie J Miller, Christina Baik, Joel W Neal, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
September 5, 2014
T-cell immunotherapy: looking forward
Jacqueline Corrigan-Curay, Hans-Peter Kiem, David Baltimore, et al.
Journal for Immunotherapy of Cancer
|
July 2, 2024
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
Sushma Bharadwaj, Eric Lau, Mark P Hamilton, et al.
Cancer Discovery
|
October 31, 2015
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo, David M Barrett, Kathryn L Black, et al.
Blood
|
July 5, 2024
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
Hrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 29, 2021
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew Dj Pearson, Claudia Rossig, Crystal Mackall, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas
Michelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Cancer Cell
|
June 13, 2025
CSF1R<sup>+</sup> myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
David Stahl, Philipp Gödel, Hyatt Balke-Want, et al.
Nature
|
November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomas
Michelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature
|
November 29, 2024
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomas
Michelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Page
of 4